Expediting the drug discovery for ideal leads against SARS-CoV-2 via molecular docking of repurposed drugs
- 27 September 2022
- journal article
- research article
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 41 (16) , 7949-7965
Abstract
SARS-CoV-2, the novel coronavirus spreading worldwide urges the need to repurpose drugs that can quickly enter clinical trials to combat the on-going global pandemic. A cluster of proteins are encoded for by the viral genome, each assuming a critical role in pathogen endurance inside the host. To handle the adverse circumstances, robust virtual strategies such as repurposing are coming to the fore due to being economical, efficient and rapid. Five FDA approved repurposed drugs proposed to act as inhibitors by targeting SARS-CoV-2 were used for initial evaluation via molecular docking. Moreover, a comparative analysis of the selected SARS-CoV-2 proteins against five ligands (Clemizole hydrochloride, Exemestane, Nafamostat, Pregnenolone and Umifenovir) was designed. In this regard, non-structural proteins (nsp3, nsp5, nsp10, nsp12 and nsp15), structural proteins (Spike, Nucleocapsid protein) and accessory proteins (ORF 3a, ORF 7a and ORF 9 b) were selected. Here, we aim to expedite the search for a potential drug from the five FDA approved repurposing drugs already in use for treatment of multiple diseases. Based on docking analysis, Umifenovir and Pregnenolone are suggested to show potential inhibitory effects against most of the SARS-CoV-2 proteins. These drugs are noteworthy since they exhibit high binding towards target proteins and should be used as lead compounds towards in vitro and in vivo studies. Communicated by Ramaswamy H. SarmaKeywords
Funding Information
- Department of Science and Technology ((DST)-ECRA/)
- Department of Science and Technology (/)
- Department of Science and Technology (2)
- Department of Biotechnology ((DBT)-BT/)
- Department of Biotechnology (4/BRB/10/)
- Department of Biotechnology (/)
This publication has 54 references indexed in Scilit:
- Drug repurposing in kidney diseaseKidney International, 2018
- SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small moleculesScientific Reports, 2017
- Transient receptor potential canonical 4 and 5 proteins as targets in cancer therapeuticsEuropean Biophysics Journal, 2016
- A Randomized, Double-Blind, Placebo-Controlled Trial of Pregnenolone for Bipolar DepressionNeuropsychopharmacology, 2014
- SARS-CoV ORF1b-encoded nonstructural proteins 12–16: Replicative enzymes as antiviral targetsAntiviral Research, 2014
- Pregnenolone Rescues Schizophrenia-Like Behavior in Dopamine Transporter Knockout MicePLOS ONE, 2012
- Membranotropic Effects of Arbidol, a Broad Anti-Viral Molecule, on Phospholipid Model MembranesThe Journal of Physical Chemistry B, 2010
- Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative GroupJournal of Clinical Oncology, 2008
- Antiallergic effects of H1‐receptor antagonistsAllergy, 2000
- Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy functionJournal of Computational Chemistry, 1998